In Vitro Diagnostic Kits
The IBDX® panel is the most reliable and cost-effective blood test for Inflammatory Bowel Disease (IBD) diagnosis, stratification (CD vs. UC) and determing Crohn's Disease severity with improved sensitivity and specificity. ALCA, ACCA and AMCA our novel sugar-antigens together with the gASCA , Glycominds' 2nd generation and improved ASCA, provide the most sensitive and specific tests available to aid in the diagnosis of Crohn’s Disease.
Prognostics Clinical Summary
Numerous studies show the IBDX® test delivers consistent, reproducible and accurate results. The IBDX® test provides clinically valuable information clinicians can use to assess the risk of Crohn's Disease patients developing complications and/or requiring surgery, based on over 2,000 patients studied to date. The IBDX® test can confirm your decision to treat early with anti-TNF biologics and gives patients more confidence in their decisions regarding such treatment. Crohn’s Disease positive for two or more of the IBDX® assay have a significantly higher risk for developing disease complications and/or requiring surgery.
ORDER:
 |
| Product |
Catalog No. |
Test Size |
|
|
S701100 |
8*12 |
| IBDX® gASCA IgA |
S705100 |
8*12 |
| IBDX® ACCA IgA |
C702100 |
8*12 |
| IBDX® ALCA IgG |
L703100 |
8*12 |
| IBDX® AMCA IgG |
M704100 |
8*12 |
|
IBDX® kits are not available in the US.
The IBDX® technology is available in the United States via a Laboratory Developed Test provided by several clinical laboratories.
IBDX® is a registered trademark of Glycominds Ltd.
|
|